UPAR Ultra Risk Parity ETF UPAR
Set alert
15.24 USD -0.13 -0.87%
At close · Oct 30
15.24 0.00 0.00%
After hours · Oct 30, 7:30 PM ET
15.24 Day range 15.26
14.89 52-week range 17.71
- YTD
- -1.39%
- 1 year
- -1.84%
- Open
- 15.26
- Prev close
- 15.38
- Mkt cap
- 54.94M
- Vol
- 795
- Avg vol
- 10.38K
- EPS
- 0.825617
- P/E
- 18.46
- Div yield
- 0.00%
More statistics
- Low
- 15.24
- High
- 15.26
- Forward P/E
- 0.00
- Beta
- 0.00
- Short ratio
- 0.00
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 13.94
- 200-d avg
- 13.89
3M chart
Events in this range
- Sep 28, 2026Dividend: 0.10887
Signals (14)
| Name | Date | Ago |
|---|---|---|
| SMA: Bearish | Oct 30, 2026 | 2 days ago |
| SMA: Bullish | Oct 22, 2026 | 1 week ago |
| MACD: Buy Signal | Oct 12, 2026 | 2 weeks ago |
| RSI: Oversold | Oct 7, 2026 | 3 weeks ago |
| RSI: Oversold | Sep 28, 2026 | 1 month ago |
| SMA: Bearish | Sep 23, 2026 | 1 month ago |
| SMA: Bullish | Sep 22, 2026 | 1 month ago |
| SMA: Bearish | Sep 10, 2026 | 1 month ago |
| SMA: Bearish | Sep 10, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 1, 2026 | 2 months ago |
| RSI: Overbought | Aug 25, 2026 | 2 months ago |
| SMA: Bullish | Aug 19, 2026 | 2 months ago |
| SMA: Bullish | Aug 13, 2026 | 2 months ago |
| SMA: Bullish | Aug 4, 2026 | 2 months ago |
Key statistics
- Market cap
- 0
- Enterprise value
- 0
- Trailing P/E
- 15.61
- Forward P/E
- 0.00
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- EPS (TTM)
- 0.00
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Shares outstanding
- 0
- Short % of float
- 0.00%
- 50-day average
- 13.94
- 200-day average
- 13.89
About UPAR Ultra Risk Parity ETF
The fund is an actively-managed ETF that seeks to replicate the returns of the Advanced Research Ultra Risk Parity Index (the “UPAR Index”). The UPAR Index is designed to provide leveraged exposure to the RPAR Index by using an implied financing rate to target 1.4 times the asset class exposures of the RPAR Index at each quarterly rebalance. It is non-diversified.
News
- Hedge Funds Swap Yen For Dollar In New Carry Trade Strategy: Report
- NorthStar Medical Radioisotopes Provides Updates on Corporate Progress and Upcoming Milestones
- Conjugated Monoclonal Antibodies Global Market Research Report 2022 - ResearchAndMarkets.com
- Conjugated Monoclonal Antibodies Global Market Report 2021: COVID-19 Growth and Change to 2030 - ResearchAndMarkets.com
- Toroso Launches Leveraged ETF for Investors Seeking More Upside
- Real-Time Monitoring of Melanoma Cell Invasion Helps Scientists Elucidate Key Regulators of Metastasis
- Onxeo concède à Monopar Therapeutics une licence mondiale exclusive de Validive®, développé dans le traitement de la mucite orale sévère
- Onxeo Grants Exclusive Worldwide License of Validive® Developed for the Treatment of Oral Severe Mucositis to Monopar Therapeutics
Your note
Sign in to keep a note on UPAR — it syncs with the Stock Master app.